PLoS Genetics (Jan 2013)

Causal and synthetic associations of variants in the SERPINA gene cluster with alpha1-antitrypsin serum levels.

  • Gian Andri Thun,
  • Medea Imboden,
  • Ilaria Ferrarotti,
  • Ashish Kumar,
  • Ma'en Obeidat,
  • Michele Zorzetto,
  • Margot Haun,
  • Ivan Curjuric,
  • Alexessander Couto Alves,
  • Victoria E Jackson,
  • Eva Albrecht,
  • Janina S Ried,
  • Alexander Teumer,
  • Lorna M Lopez,
  • Jennifer E Huffman,
  • Stefan Enroth,
  • Yohan Bossé,
  • Ke Hao,
  • Wim Timens,
  • Ulf Gyllensten,
  • Ozren Polasek,
  • James F Wilson,
  • Igor Rudan,
  • Caroline Hayward,
  • Andrew J Sandford,
  • Ian J Deary,
  • Beate Koch,
  • Eva Reischl,
  • Holger Schulz,
  • Jennie Hui,
  • Alan L James,
  • Thierry Rochat,
  • Erich W Russi,
  • Marjo-Riitta Jarvelin,
  • David P Strachan,
  • Ian P Hall,
  • Martin D Tobin,
  • Morten Dahl,
  • Sune Fallgaard Nielsen,
  • Børge G Nordestgaard,
  • Florian Kronenberg,
  • Maurizio Luisetti,
  • Nicole M Probst-Hensch

DOI
https://doi.org/10.1371/journal.pgen.1003585
Journal volume & issue
Vol. 9, no. 8
p. e1003585

Abstract

Read online

Several infrequent genetic polymorphisms in the SERPINA1 gene are known to substantially reduce concentration of alpha1-antitrypsin (AAT) in the blood. Since low AAT serum levels fail to protect pulmonary tissue from enzymatic degradation, these polymorphisms also increase the risk for early onset chronic obstructive pulmonary disease (COPD). The role of more common SERPINA1 single nucleotide polymorphisms (SNPs) in respiratory health remains poorly understood. We present here an agnostic investigation of genetic determinants of circulating AAT levels in a general population sample by performing a genome-wide association study (GWAS) in 1392 individuals of the SAPALDIA cohort. Five common SNPs, defined by showing minor allele frequencies (MAFs) >5%, reached genome-wide significance, all located in the SERPINA gene cluster at 14q32.13. The top-ranking genotyped SNP rs4905179 was associated with an estimated effect of β = -0.068 g/L per minor allele (P = 1.20*10(-12)). But denser SERPINA1 locus genotyping in 5569 participants with subsequent stepwise conditional analysis, as well as exon-sequencing in a subsample (N = 410), suggested that AAT serum level is causally determined at this locus by rare (MAF<1%) and low-frequent (MAF 1-5%) variants only, in particular by the well-documented protein inhibitor S and Z (PI S, PI Z) variants. Replication of the association of rs4905179 with AAT serum levels in the Copenhagen City Heart Study (N = 8273) was successful (P<0.0001), as was the replication of its synthetic nature (the effect disappeared after adjusting for PI S and Z, P = 0.57). Extending the analysis to lung function revealed a more complex situation. Only in individuals with severely compromised pulmonary health (N = 397), associations of common SNPs at this locus with lung function were driven by rarer PI S or Z variants. Overall, our meta-analysis of lung function in ever-smokers does not support a functional role of common SNPs in the SERPINA gene cluster in the general population.